Results 81 to 90 of about 598,834 (266)

Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database

Scientific Reports
Fulvestrant, as the first selective estrogen receptor degrader, is widely used in the endocrine treatment of breast cancer. However, in the real world, there is a lack of relevant reports on adverse reaction data mining for fulvestrant.
Guisen Yin, Guiling Song, Shuyi Xue, Fen Liu   +3 more
doaj   +1 more source

Epidemiology of medical adverse events: perspectives from a single institute in Taiwan

Journal of the Formosan Medical Association, 2016
Epidemiology data of medical adverse events (MAEs) are crucial for patient safety policymaking. However, no epidemiological data on MAE exist in Taiwan.
Chen-Hsu Wang, Chung-Liang Shih, Wen-Jing Chen, Sheng-Hui Hung, Wei-Jia Jhang, Li-Ju Chuang, Pa-Chun Wang   +6 more
doaj   +1 more source

Enhancing Adverse Drug Event Detection with Multimodal Dataset: Corpus Creation and Model Development [PDF]

The mining of adverse drug events (ADEs) is pivotal in pharmacovigilance, enhancing patient safety by identifying potential risks associated with medications, facilitating early detection of adverse events, and guiding regulatory decision-making. Traditional ADE detection methods are reliable but slow, not easily adaptable to large-scale operations ...
arxiv   +1 more source

Adversity Index for Clinical Trials: An Inclusive Approach for Analysis of Safety Data [PDF]

arXiv, 2018
This paper proposes a new method for analysis of adverse event data in clinical trials. The method is illustrated by application to data on 4 phase III clinical trials, two on breast cancer and two on diabetes mellitus.
arxiv  

Assessing proton plans with three different beam delivery systems versus photon plans for head and neck tumors

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose To compare plan quality among photon volumetric modulated arc therapy (VMAT) and intensity‐modulated proton therapy (IMPT) with robustness using three different proton beam delivery systems with various spot size (σ) ranges: cyclotron‐generated proton beams (CPBs) (σ: 2.7–7.0 mm), linear accelerator proton beams (LPBs) (σ: 2.9–5.5 mm),
Tara Gray, Chieh‐Wen Liu, Saeed Ahmed, Anna Maria Kolano, Jeremy Donaghue, Shlomo Koyfman, Neil Woody, Shauna R. Campbell, Jonathan B. Farr, Ping Xia   +9 more
wiley   +1 more source

The Adverse Event Paradox

Philosophy of Medicine, 2022
Thomas Milovac
doaj   +1 more source

Vonoprazan-associated infection: an analysis of the Japanese Adverse Drug Event Report and the FDA Adverse Event Reporting System

Therapeutic Advances in Drug Safety
Background: Prolonged or excessive use of acid suppressants may increase the risk of Clostridioides difficile infection (CDI) by altering the intestinal microecosystem.
Mengling Ouyang, Shupeng Zou, Qian Cheng, Xuan Shi, Yazheng Zhao, Minghui Sun   +5 more
doaj   +1 more source

Cardiovascular toxicity of tisagenlecleucel in children and adolescents: analysis of spontaneous reports submitted to FAERS

Frontiers in Immunology
BackgroundThe advent of tisagenlecleucel has been a major advance in the pharmacological treatment of relapsed/refractory B-cell acute lymphoblastic leukemia in children and adolescents.
Ganggang Wang, Lin Su, Yanjun Liu, Xiaohan Yang, Yi Li, Qi Mei, Qi Mei, Wen Gao   +7 more
doaj   +1 more source

Effects of cardiac motion on dose distribution during stereotactic arrhythmia radioablation treatment: A simulation and phantom study

Journal of Applied Clinical Medical Physics, EarlyView.
Abstract Purpose Cardiac motion may degrade dose distribution during stereotactic arrhythmia radioablation using the CyberKnife system, a robotic radiosurgery system. This study evaluated the dose distribution changes using a self‐made cardiac dynamic platform that mimics cardiac motion. Methods The cardiac dynamic platform was operated with amplitudes
Takayuki Miyachi, Takeshi Kamomae, Fumitaka Kawabata, Kuniyasu Okudaira, Mariko Kawamura, Shunichi Ishihara, Shinji Naganawa   +6 more
wiley   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for sunitinib

Frontiers in Pharmacology
BackgroundSunitinib is approved for the treatment of metastatic renal cell carcinoma (mRCC), imatinib-resistant gastrointestinal stromal tumors (GIST), and advanced pancreatic neuroendocrine tumors (PNET).
Xusheng Zhang, Xiuli Ren, Tianyu Zhu, Wanjin Zheng, Wanjin Zheng, Chengwu Shen, Cuicui Lu   +6 more
doaj   +1 more source